Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention

  Leukemia

  Free Subscription


30.05.2022

2 Am J Hematol
2 Ann Hematol
1 Blood
2 BMC Cancer
1 Cancer
2 Exp Hematol
1 Genes Chromosomes Cancer
3 Leuk Lymphoma
1 Leuk Res
3 Leukemia
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. BEELEN DW, Stelljes M, Remenyi P, Wagner-Drouet EM, et al
    Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26620.
    PubMed         Abstract available

  2. VABRE C, Zelmat Y, Gauthier M, Pajiep M, et al
    Incident users of tyrosine kinase inhibitors in chronic myeloid leukemia patients: analysis of anticancer treatment trajectories - A French population-based study using the French national health data system.
    Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26621.
    PubMed        


    Ann Hematol

  3. SAITO K, Ichikawa S, Ohtomo R, Hatta S, et al
    Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia.
    Ann Hematol. 2022 May 25. pii: 10.1007/s00277-022-04875.
    PubMed        

  4. KOSCHADE SE, Stratmann JA, Finkelmeier F, Wagner S, et al
    Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.
    Ann Hematol. 2022 May 20. pii: 10.1007/s00277-022-04862.
    PubMed         Abstract available


    Blood

  5. SEMENZATO G, Zambello R
    Interrogating molecular genetics to refine LGLL classification.
    Blood. 2022;139:3002-3004.
    PubMed        


    BMC Cancer

  6. YANG J, Lu F, Ma G, Pang Y, et al
    Role of CDH23 as a prognostic biomarker and its relationship with immune infiltration in acute myeloid leukemia.
    BMC Cancer. 2022;22:568.
    PubMed         Abstract available

  7. PLATZBECKER U, Chromik J, Kronke J, Handa H, et al
    Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
    BMC Cancer. 2022;22:569.
    PubMed         Abstract available


    Cancer

  8. LOKE J, Labopin M, Craddock C, Cornelissen JJ, et al
    Additional cytogenetic features determines outcome in patients allografted for TP53 mutant acute myeloid leukemia.
    Cancer. 2022 May 25. doi: 10.1002/cncr.34268.
    PubMed         Abstract available


    Exp Hematol

  9. JUNCO JJ, Zorman B, Gant VU Jr, Munoz J, et al
    CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.
    Exp Hematol. 2022;110:34-38.
    PubMed         Abstract available

  10. GERRITSEN M, Hilgendorf S, Yi G, Wierenga ATJ, et al
    Presence of mutant p53 increases stem-cell frequency and is associated with reduced binding to classical TP53 binding sites in cell lines and primary AMLs.
    Exp Hematol. 2022 Mar 18. pii: S0301-472X(22)00128.
    PubMed         Abstract available


    Genes Chromosomes Cancer

  11. LEE WY, Gutierrez-Lanz EA, Xiao H, McClintock D, et al
    ERG amplification is a secondary recurrent driver event in myeloid malignancy with complex karyotype and TP53 mutations.
    Genes Chromosomes Cancer. 2022;61:399-411.
    PubMed         Abstract available


    Leuk Lymphoma

  12. QIN T, Cheng Y, Wang X
    RNA-binding proteins as drivers of AML and novel therapeutic targets.
    Leuk Lymphoma. 2022;63:1045-1057.
    PubMed         Abstract available

  13. SAUMELL S, Fernandez-Serrano M, Mesa A, Lopez-Cadenas F, et al
    Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
    Leuk Lymphoma. 2022;63:1227-1235.
    PubMed         Abstract available

  14. LI J, Liao D, Wang F, Wang Z, et al
    RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo.
    Leuk Lymphoma. 2022;63:1167-1179.
    PubMed         Abstract available


    Leuk Res

  15. KIM T, Ahn JS, Son MH, Novitzky-Basso I, et al
    Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
    Leuk Res. 2022;118:106858.
    PubMed         Abstract available


    Leukemia

  16. AGATHANGELIDIS A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, et al
    Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL.
    Leukemia. 2022 May 25. pii: 10.1038/s41375-022-01604.
    PubMed         Abstract available

  17. GRIMM J, Bhayadia R, Gack L, Heckl D, et al
    Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core.
    Leukemia. 2022 May 24. pii: 10.1038/s41375-022-01603.
    PubMed        

  18. JAKEL H, Taschler M, Jung K, Weinl C, et al
    Inability to phosphorylate Y88 of p27(Kip1) enforces reduced p27 protein levels and accelerates leukemia progression.
    Leukemia. 2022 May 21. pii: 10.1038/s41375-022-01598.
    PubMed         Abstract available


    PLoS One

  19. HERNANDEZ VA, Carvajal-Moreno J, Wang X, Pietrzak M, et al
    Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIalpha intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.
    PLoS One. 2022;17:e0265794.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: